December 10, 2024
CatalYm Highlights Visugromab’s Potential to Treat Cachexia in Cancer Patients at International SCWD Conference
CatalYm Highlights Visugromab’s Potential to Treat Cachexia in Cancer Patients at International SCWD...
Read More
July 16, 2024
CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab
CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development...
Read More